

**BIOGRAPHICAL SKETCH**

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.

Follow this format for each person **DO NOT EXCEED FOUR PAGES**

NAME Rodney L. Page		POSITION TITLE Professor	
eRA COMMONS USER NAME RODNEY_PAGE			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
University of Colorado	BS	1975	Chemistry/Math
Georgetown University	MS	1977	Medical Physiology
Colorado State University	DVM	1981	DVM

**A. Positions and Honors:**

- 1981-1984 Internship/Oncology Residency, Animal Medical Center, 510 E. 62nd St NYC, NY 10021  
 1984-1999 Assistant - Full Professor. North Carolina State University College of Veterinary Medicine, 4700 Hillsborough St. Raleigh, NC 27606.  
 1991-present Adjunct Assistant Professor - Duke University Medical Center, Dept of Radiation Oncology, Durham, NC 27710.  
 1999 -2010 Professor, Cornell University, College of Veterinary Medicine.  
 1999 - 2010 Director, Sprecher Institute for Comparative Cancer Research, Cornell University  
 2005 -2010 Chair, Dept of Clinical Sciences, Cornell University  
 2010 – current Professor & Director, Flint Animal Cancer Center, College of Veterinary Medicine/Biomed Science, Colorado State University, Fort Collins, CO 80523

**Professional Societies/Honors:**

American College of Veterinary Internal Medicine - Diplomate - Specialties of Oncology and Internal Medicine. Ed Adv Board for *Clinical Cancer Research* and *J of Vet and Comp Onc.* – 2002 –2006.  
 Pfizer Award for Research Excellence – 1998. John E. McCoy Award for exceptional contributions to Veterinary Medicine. Washington State University – College of Veterinary Medicine. 2004

**B. Selected peer-reviewed publications:** (selected publications from total of 114 refereed manuscripts)

- Waddle JR, Fine RL, Case BC, Trogdon ML, Tyczkowska K, Frazier D, **Page, RL.** Phase I and pharmacokinetic analysis of high-dose tamoxifen plus chemotherapy in normal and tumor-bearing dogs. *Cancer Chemotherapy and Pharmacology* 44:74-80, 1999.  
 LaRue, S.M., Fox, M.H., Ogilvie, G.K., **Page, R.L.**, Getzy, D.M., Thrall, D.E., Johnson, J.L., Dewhirst, M.W., and Gillette, E.L.: Tumour cell kinetics as predictors of response in canine lymphoma treated with chemotherapy alone or combined with whole body hyperthermia. *Int. J. Hyperthermia* 15:475-486, 1999.  
 Thrall DE, LaRue SM, Powers BE, **Page RL**, Johnson J, George SL, Kornegay JN, McEntee MC, Dewhirst MW, Gillette EL. Use of whole body hyperthermia as a method to uniformly heat inaccessible tumors: A phase III trial in canine brain masses. *International J of Hyperthermia* – 15:383-388, 1999  
 Vujaskovic, J., Poulson, J.M., Gaskin, A.A., Thrall, D.E., **Page, R.L.**, Charles, H.C., MacFall, J.R., Brizel, D.M., Meyer, R.E., Prescott, D.M., Samulski, T.V., and Dewhirst, M.W.: Temperature-Dependent Changes in Physiologic Parameters of Spontaneous Canine Soft Tissue Sarcomas After Combined Radiotherapy and Hyperthermia Treatment. *Int. J. Radiat. Oncol. Biol. Phys.* 46:179-185, 2000.

- Prescott, DM, Charles CC, Poulson JM, **Page RL**, Thrall DE, Vujaskovic Z, Dewhirst MW. The relationship between intracellular and extracellular pH in spontaneous canine tumors. *Clinical Cancer Research* 6:2501-2505, 2000.
- Case BC, Hauck ML, Yeager R, **Page RL**. Pharmacokinetics and pharmacodynamics of GW395058, a pegylated peptide agonist of the thrombopoietin receptor, in a large animal model of chemotherapy induced thrombocytopenia. *Stem Cells* 18:360-365, 2000.
- Page, RL**, Hughes CS, Huyen S, Sagris J, Trogdon M. Modulation of P-glycoprotein-mediated doxorubicin resistance in canine cell lines. *Anticancer Research* – 20:3533-3538, 2000.
- Poulson JM, Dewhirst MW, Gaskin AA, Vujaskovic Z, Samulski TV, Prescott DM, Meyer RE, **Page RL**, Thrall DE. Acute pancreatitis associated with administration of a nitric oxide synthase inhibitor in tumor-bearing dogs. *In Vivo* 14:709-714, 2000.
- Maitra, R, Halpin, PA, Carlson, KH, **Page, RL**, Paik, DY, Moyer, D, Matthew, OL, Stanton, BA, Hamilton, JW. Differential effects of mitomycin C and doxorubicin on P-glycoprotein expression. *Biochem J* 355(3):617-623, May 2001.
- Antonyak, MA, Ugra SS, Lee, DA, Boehm JE, Combs C, Zgola M, **Page RL**, Cerione RA. Effects of Tissue transglutaminase on retinoic acid-induced cellular differentiation and protection against apoptosis. *J Biol Chem* 276:33582-33586, 2001.
- McEntee MC, Silverman JA, Rassnick KM, Zgola MM, Chan AO, Tau PT, **Page RL**. Enhanced bioavailability of oral docetaxel by co-administration of cyclosporine in dogs and rats. *Veterinary and Comparative Oncology* 1:105-112, 2003.
- Manor D, Shmidt EN, Budhu A, Nikitin AF, Zgola M, **Page RL**, Noy N and Nikitin AY. Suppression of mammary tumor growth by cellular retinoic acid binding protein II. *Cancer Res* 63:4426-4433, 2003.
- McEntee MC, **Page RL**, Theon A, Erb H, Thrall DE. Malignant tumor formation in dogs previously irradiated for oral acanthomatous epulis. *Vet Radiol & US* 45:357-361, 2004.
- Antonyak MA, Miller AM, Jansen JM, Boehm JE, Balkman CE, Wakshlag JJ, **Page RL**, Cerione RA. Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibits doxorubicin-induced apoptosis in human breast cancer cells. *J Biol Chem.* 279(40):41461-7, 2004
- Bailey DB, Rassnick KM, Erb HN, Dykes NL, Hoopes PJ, **Page RL**. Effect of glomerular filtration rate on carboplatin clearance and myelotoxicity in tumor-bearing cats. *Am J of Veterinary Research* 65:1502-1507, 2004.
- Wakshlag JJ, McNeill CJ, Antonyak M, Boehm J, Fuji R, Balkman CE, Zgola M, Cerione R, **Page RL**. Expression and activity of transglutaminase II in normal tissue and spontaneous tumors of companion animals. *J Comp Pathology* Feb-Apr;134(2-3):202-10, 2006.
- Rassnick KM, Moore A, Northrup N, Kristal O, Lewis L, Bequieu B, **Page RL**. Phase I and pharmacokinetic study of ifosfamide in cats. *Am J Vet Research* Mar;67(3):510-6, 2006.
- Rassnick KM, Moore A, Northrup N, Kristal O, Lewis L, Bequieu B, **Page RL**. Phase II study of ifosfamide in cats with soft tissue sarcomas. *Am J Vet Research* Mar;67(3):517-23, 2006.
- McEntee MC, Rassnick KM, Lewis LD, Zgola MM, Beaulieu BB, Balkman CE, **Page RL**. Phase I and Pharmacokinetic Evaluation of the Combination of Oral Docetaxel and Cyclosporin A in Tumor-Bearing Dogs. *Am J Vet Res* Jun;67(6): 1057-62, 2006.
- Ying V, Haverstic K, **Page RL**, Saltzman M. Efficacy of camptothecin and polymer-conjugated camptothecin in tumor spheroids and solid tumors. *J Biomaterials Science, Polymer Edition*, 18:1283-1299, 2007.
- Rassnick KM, Muindi JR, Johnson CS, Balkman CE, Ramnath N, Yu W, Engler KL, **Page RL**, Trump DL. *In Vitro* and *In Vivo* Evaluation of Combined Calcitriol and Cisplatin in Dogs with Spontaneously Occurring Tumors. *Cancer Chemotherapy and Pharmacology* 62(5):881-91, 2008.
- Field MS, Anguera MC, **Page RL**, Stover PJ. 5,10-Methenyltetrahydrofolate Synthetase Activity is Increased in Tumors and Modifies the Efficacy of Antipurine LY309887. *Archive of Biochemistry and Biophysics* – in press 2008.